Highest-materiality recent filing
Hawkins Q4 sales record $265.9M, FY sales $1.1B; FY diluted EPS $3.91 down 3%
Record Q4 sales $265.9M (+8% YoY); FY sales $1.1B (+11%) driven by Water Treatment +22%.
Hawkins Q3 FY2026 revenue $244.1M (+8% YoY); EPS $0.69 (-4%) on acquisition costs
Net income $14.3M vs $15.0M YoY; diluted EPS $0.69 vs $0.72; pro forma EPS up ~10% if WaterSurplus had closed earlier.
Hawkins reports record Q2 revenue of $280M, EPS down 7% on acquisition costs
Revenue $280.4M (+14% YoY); Water Treatment +21%, Industrial +11%, Food & Health Sciences +2%.
Hawkins realigns reporting segments to Water Treatment, Food & Health Sciences, Industrial Solutions
New segments: Water Treatment (unchanged), Food & Health Sciences (includes nutrition, food, ag, pharma), Industrial Solutions.
Hawkins Q1 FY2026: record revenue $293M, EPS $1.40, Water Treatment sales +28%
Revenue $293.3M (+15% YoY); diluted EPS $1.40 vs $1.38; adjusted EBITDA $57.6M (+13%).
Hawkins reports record FY2025 EPS $4.03, sales $974.4M; sees FY2026 revenue >$1B
Q4 diluted EPS $0.78 (+18% YoY); sales $245.3M (+10% YoY, record quarter).
Hawkins ups revolving credit facility to $400M, draws $150M for WaterSurplus acquisition
Revolving credit facility increased to $400M from prior $0M; includes $10M LC and $25M swingline subfacilities.
Revenue $226.2M (+8% YoY); net income $15.0M, diluted EPS $0.72 vs $0.71.
Hawkins Q2 FY2025: Record revenue $247M, EPS $1.16, adjusted EBITDA $46.3M
Revenue $247.0M (+4% YoY); Water Treatment up 23% to $124.5M; Industrial -9%, Health & Nutrition -12%.
Hawkins Q1 FY2025: record revenue $255.9M, EPS $1.38, adjusted EBITDA +25%
Revenue $255.9M (+2% YoY); Water Treatment segment grew 25% to $117.2M, becoming largest segment.
Record diluted EPS $3.59 for FY2024, up 26% from $2.86; Q4 EPS $0.66, up 20% YoY.
Hawkins Q3 EPS $0.71, up 39% YoY; Water Treatment sales +20%
Sales of $208.5M, down 5% YoY; net income $14.9M vs $10.7M last year.
Hawkins Q2 FY2024 EPS $1.10, record gross profit $53.9M, Water Treatment sales up 17%
Net income $23.2M ($1.10 diluted EPS), up 28% from $0.86 in prior-year quarter.
Hawkins Q1 FY2024: Record sales $251M, EPS $1.12 (+19% YoY); Water Treatment up 19%
Net income $23.4M ($1.12 diluted EPS) vs $19.7M ($0.94) a year ago, +19%.
Hawkins reports record FY2023 sales of $935M, EPS $2.86, up 17% YoY
Q4 sales $228.1M (record); diluted EPS $0.55, up 10% YoY; adjusted EBITDA $27.0M, +21%.
Hawkins reports record Q3 fiscal 2023: sales $219.2M (+17%), EPS $0.51 (+6%)
Net income $10.7M ($0.51 diluted) vs $10.2M ($0.48) in prior year quarter.
Hawkins reports record Q2; sales up 32% to $241.2M, EPS $0.86 (+28%); guides Q3 flat YoY
Sales $241.2M (+32% YoY); all three segments grew; Industrial +37%, Water Treatment +39%, Health & Nutrition +7%.
Hawkins reports record Q1 FY2023 sales $246.5M, EPS $0.94, up 19% YoY
Q1 sales $246.5M (+36% YoY); diluted EPS $0.94 (+19%); gross profit $46.7M (+20%); all records.
Hawkins reports record Q4 sales $223M (+37% YoY), full-year EPS $2.44 (+26%)
Record annual sales $774.5M (+30% YoY); net income $51.5M (+26%); adjusted EBITDA $99.7M (+19%).
Hawkins reports Q3 fiscal 2022 record sales $187.1M, EPS $0.48, up 30% YoY
Record quarterly sales $187.1M, up 31% YoY; trailing 12-month revenue $714.5M.
Hawkins Q2 FY2022: record sales $183.3M (+24% YoY), diluted EPS $0.67 (+18%)
Industrial sales up 36% to $83.2M; Water Treatment +25% to $62.1M on strong demand and acquisitions.
Hawkins Q1 FY2022: Record sales $181.2M, EPS $0.79, up 44% YoY; dividend raised 12%
Record quarterly sales of $181.2M (+27% YoY); record gross profit $39.0M (+26%); record operating income $22.1M (+39%).
On May 13, 2026, Shirley A. Rozeboom, Vice President – Stauber, was determined to no longer be an “executive officer” of Hawkins, Inc. (the “Company”), effective as of the same date.
On October 27, 2021, the Board of Directors of Hawkins, Inc. (the “Company”) appointed Jeffrey E. Spethmann to fill a newly created vacancy on its Board of Directors.
Max materiality 0.85 · Median 0.70 · Most common event earnings